Eiffel Technologies is focused on the re-engineering of drugs using its Super Critical Fluid (SCF) technology platform to create a unique nanosized particulates. They have the ability to reformulate and improve the solubility and bioavailability of pharmaceuticals, potentially leading to enhanced drug performance and delivery. This technology can also provide alternative formulations for drugs in late-stage development, as well as for blockbuster drugs that are facing generic competition and are in need of patent life extensions.
Eiffel has successfully re-engineered insulin using proprietary Super Critical Fluid processing techniques, that has reduced the insulin particle size by a factor of 1,000 to produce a nanosized drug, which may be suitable for other forms of delivery, including inhalational and transdermal.
Inhalable and transdermal insulin are the "holy grail" of diabetes treatment, a 5 billion dollar per year industry.
Here is an article from the BBC on Eiffel's insulin re-engineering process:
http://news.bbc.co.uk/2/hi/health/2236023.stm
"Scientists reduced insulin to the smoke-like substance using a process called nanomising.
A gas is put under extremely high pressure so that it becomes "supercritical" and behaves like a liquid.
Normal insulin is then dissolved in this liquid before it is suddenly decompressed, creating insulin particles which measure less than 100 nanometres across."
Eiffel is collaberating with several pharmaceutical and drug delivery companies for use of their oral or transdermal re-engineered insulin. At 12 cents Australian, this is a highly speculative play. This company reminds me of SkyePharma (SKYE) and Nektar Therapeutics (NKTR) in their early days. Now both $10, and $20 dollar stocks respectively.
Best regards,
nanobrian" the share is now trading at 1.3 cents. Highly speculative - I hold at a loss. DYOR.
EIF Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held